A Look At BridgeBio Pharma (BBIO) Valuation After Positive Phase 3 PROPEL 3 Achondroplasia Results

BridgeBio Pharma (BBIO) has become a focus for investors after reporting positive topline results from its global Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia.

See our latest analysis for BridgeBio Pharma.

The positive PROPEL 3 data sits alongside a very strong 1-year total shareholder return of 113.72% and a roughly 7x total shareholder return over 3 years. The 90-day share price return of 15.73% suggests momentum has recently picked up again, despite a softer year-to-date share price return reflecting a 3.05% decline.

If this biotechnology news has you thinking about where else growth stories might emerge, it could be worth scanning 25 healthcare AI stocks to see what other health-focused opportunities are turning heads right now.

With shares up sharply over the past year and analyst targets still sitting above the current US$75.85 price, the key question now is whether BridgeBio remains undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 15.5% Undervalued

Simply Wall St’s most followed narrative puts BridgeBio Pharma’s fair value at about $89.79 per share versus the recent $75.85 close, framing a valuation gap that hinges heavily on its late stage genetic disease portfolio.

The company's late-stage pipeline, with three Phase III readouts imminent across high unmet need rare disease indications, positions BridgeBio to leverage advancements in biotechnology for potential first-to-market and best-in-class therapies, creating the opportunity for multiple revenue inflection points and margin improvement as the portfolio diversifies.

Read the complete narrative.

Curious how a loss making biotech earns a premium valuation tag? This narrative leans on sharp revenue expansion, margin flip, and a future earnings multiple usually reserved for sector leaders. Want to see which specific growth, profitability, and discount rate assumptions are doing the heavy lifting here?

Result: Fair Value of $89.79 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh concentration in Attruby, as well as the possibility of late stage trial or regulatory setbacks that could quickly challenge this upbeat pipeline case.

Find out about the key risks to this BridgeBio Pharma narrative.

Another Way to Look at the Price Tag

The fair value narrative leans on future cash flows and suggests BridgeBio Pharma is undervalued, but the current P/S of 41.3x tells a different story. It is much higher than the US Biotechs average of 11.3x, the peer average of 19.1x, and even the fair ratio of 23.8x. This points to meaningful valuation risk if expectations cool. Which set of numbers do you feel more comfortable leaning on?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and caution in this article resonates with you, it is worth looking through the numbers yourself and weighing both sides quickly before sentiment shifts. A good place to start is by examining the 2 key rewards and 2 important warning signs so you can judge the balance of concerns and potential upsides for yourself.

Looking for more investment ideas?

If you stop at a single stock, you miss the bigger picture, use the Simply Wall St screener to quickly surface other opportunities that might suit your style.

• Target stability and income by reviewing 13 dividend fortresses that aim to pair generous payouts with balance sheets that can support them.
• Hunt for potential bargains by scanning 56 high quality undervalued stocks where quality fundamentals meet prices that may not fully reflect them yet.
• Prioritise resilience by checking out 80 resilient stocks with low risk scores so you can focus on companies with risk profiles that may help you sleep better at night.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com